BioSpace News Archive

Drug Development

UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints

October 18, 2018
·
8 min read
Positive Results of Orthopedic Treatment With the Use of ApoGraft™ Enriched Stem Cells Derived From Fat Tissues

Study shows significant improvement in orthopedic healing process

October 18, 2018
·
5 min read
Deals

Sonendo® and TDO® Software Expand Their Strategic Partnership

Sonendo is experiencing exponential growth due to the market response for the GentleWave® Procedure – an alternative approach to standard root canal treatment.

October 18, 2018
·
3 min read
Business

Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical Officer

Veteran of the Biopharmaceutical Industry Joins as Company Advances Two Late-stage Oncology Therapies

October 18, 2018
·
5 min read
Drug Development

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma

KEYTRUDA is First Anti-PD-1 Therapy in Combination to Improve Both OS and PFS in Advanced or Metastatic RCC, the Most Common Type of Kidney Cancer

October 18, 2018
·
25 min read
Drug Development

GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

Clinically meaningful improvement of +15 ETDRS letters in visual acuity of treated eyes at Week 72

October 18, 2018
·
7 min read
Business

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

AELIX Therapeutics will investigate the safety, immunogenicity, and efficacy of AELIX Therapeutics’ HTI vaccine and Gilead´s Toll-Like Receptor 7 agonist vesatolimod (GS-9620) in HIV-infected individuals

October 18, 2018
·
5 min read
Policy

Ascletis’ Ravidasvir NDA Proposed for Priority Review by the CFDA

Ascletis Pharma Inc. announces today the New Drug Application (NDA) of Ravidasvir is on the List of Proposed Priority Review, according to the public notification by the China Food and Drug Administration (CFDA) on Oct 17th, 2018.

October 18, 2018
·
1 min read
Biotech Beach

Delta Dental Community Care Foundation awards $131,483 grant to San Ysidro Health

The organization serves over 95,000 patients annually through a network of medical, dental, and behavioral health clinics located across San Diego County.

October 18, 2018
·
2 min read
Lone Star Bio

Marker to Present at Two Upcoming Cellular Therapy October 2018 Conferences

Marker Therapeutics, Inc. today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming cellular therapy conferences.

October 18, 2018
·
3 min read